Neohesperidin
Compiled from published pharmacological and botanical literature. Not independently verified by Herbuno. Spotted an error or have a correction? Flag it below →
| Chemical Class | Flavanone glycoside |
| Molecular Formula / CAS | C₂₈H₃₄O₁₅ · CAS 13241-33-3 |
| Primary Botanical Source(s) | Bitter orange (Citrus aurantium) |
| Plant Part | Fruit peel |
| Typical Content | A characteristic bitter flavanone glycoside of Seville/bitter orange peel, distinct from the sweet-orange-dominant flavanone hesperidin |
| Solubility / Format | Available as a high-purity standardised isolate powder |
| Sourcing Status | Product-live — genuine match via Herbuno’s bitter orange extract line |
| Buy from Herbuno | Neohesperidin 98% Powder (Bitter Orange) |
Name origin: Neohesperidin takes its name as a structural relative (isomer) of hesperidin, itself named for the mythological Hesperides gardens of golden citrus fruit; the “neo” prefix distinguishes its glycosidic linkage pattern from hesperidin proper. Traditional use: Bitter orange peel has a long traditional use in Traditional Chinese Medicine (as zhi qiao and zhi shi) and across Mediterranean folk medicine for digestive complaints, bloating and as a bitter digestive tonic, predating any chemical identification of its flavanone content. Research trajectory: Neohesperidin research has developed along two largely separate tracks: as the natural precursor for the semi-synthetic sweetener neohesperidin dihydrochalcone (produced by catalytic hydrogenation and used commercially as a high-intensity sweetening agent), and, more recently, as a bioactive compound in its own right, with a substantial and growing pharmacological literature covering neuroprotective, anti-inflammatory, antidiabetic and bone-health applications. Commercial source: Bitter orange peel is the standard commercial source of neohesperidin, and Herbuno’s standardised extract reflects this well-established, genuine botanical match.
Evidence for Neohesperidin Applications
Neohesperidin (hesperetin 7-O-neohesperidoside) is a well-characterised citrus flavanone glycoside with a broad documented pharmacological profile. A comprehensive 2022 review covering its biosynthesis, bioavailability, toxicology and pharmacology catalogued neuroprotective, anti-inflammatory, antidiabetic, antimicrobial and anticancer activities, alongside mechanistic pathways relevant to osteoporosis, gastric ulcer and cardiovascular and hepatic protection (et al. 2022). Claim strength: Moderate.
In rats fed a prolonged high-fat diet, oral neohesperidin administration (40–80 mg/kg body weight over 12 weeks) reduced markers of colorectal inflammation, including significant decreases in TNF-alpha and IL-1β, improved intestinal mucosal integrity, and favourably shifted gut microbiota composition via the JAK2/STAT3 signalling pathway (et al. 2025). This is a genuine isolated-compound rodent study with a real dosing range, distinct from broader citrus-flavonoid research generally. Claim strength: Moderate.
A dedicated review of neohesperidin alongside hesperidin and hesperetin for bone health found that these citrus flavanones exert antiosteoclastic and anti-inflammatory effects in vitro, reducing osteoclast marker expression and reactive oxygen species, while favouring osteogenic (bone-forming) activity in preosteoblastic cells; in vivo work cited in the review found these flavanones reduced trabecular bone loss and increased bone mineral density in ovariectomy models (et al. 2022). The reviewers noted that clinical research is still needed to confirm translation to human bone outcomes. Claim strength: Emerging.
Separately, neohesperidin has documented lipid-regulating effects, acting via the fibroblast growth factor 21 and AMPK/SIRT1/PGC-1alpha signalling axis in both cell and animal models of metabolic dysfunction, positioning it alongside other citrus flavanones as a candidate for further metabolic health research. This mechanistic work remains preclinical and has not yet been confirmed in dedicated human metabolic trials. Claim strength: Emerging.
For sourcing purposes, the key distinction formulators must hold is between neohesperidin (the naturally occurring flavanone glycoside discussed throughout this monograph, which is what Herbuno’s bitter orange product delivers) and neohesperidin dihydrochalcone (NHDC, E959), a distinct semi-synthetic sweetener produced by chemically hydrogenating neohesperidin. NHDC is not a natural constituent at meaningful levels and has a separate regulatory identity as a food additive; the two should never be treated as interchangeable in a sourcing specification. Claim strength: High.
Dosage & Formulator Specification
Published animal research has used neohesperidin doses in the range of 40–80 mg/kg body weight for anti-inflammatory and gut-health effects over multi-week feeding periods; no formally established human clinical dosing range exists for isolated neohesperidin specifically, distinct from the separate regulatory intake guidance that applies to the dihydrochalcone sweetener derivative.
Analytical quantification of neohesperidin is performed by HPLC; formulators should confirm with suppliers whether a stated percentage refers to the natural flavanone glycoside or the dihydrochalcone derivative, since these are chemically and functionally distinct compounds despite the shared name root, and this distinction is not always made clear in generic product listings.
Given neohesperidin’s bitter taste profile (in contrast to its sweet dihydrochalcone derivative), formulators should account for flavour masking needs in oral consumer products, particularly at higher inclusion rates aimed at matching research-relevant dosing. This bitterness is itself a useful analytical proxy during quality control, since a neohesperidin-standardised extract that tastes unexpectedly sweet may indicate cross-contamination with, or substitution by, the dihydrochalcone derivative.
Regulatory positioning for neohesperidin follows established bitter orange food-ingredient precedent in most markets, given its long traditional use; formulators should note that the related but distinct dihydrochalcone sweetener (E959/NHDC) carries its own separate food-additive regulatory approval and acceptable daily intake guidance that does not apply to the natural flavanone discussed in this monograph.
Frequently Asked Questions — Neohesperidin
No, and this is an important distinction. Neohesperidin is the naturally occurring flavanone glycoside found in bitter orange peel. Neohesperidin dihydrochalcone (NHDC, E959) is a semi-synthetic sweetener made by chemically hydrogenating neohesperidin, and is not itself a natural constituent at meaningful levels.
A comprehensive 2022 review documented neuroprotective, anti-inflammatory, antidiabetic and anticancer activities, and a dedicated rat study found neohesperidin reduced markers of high-fat-diet-induced colon inflammation and favourably altered gut microbiota over 12 weeks of supplementation.
Yes. A review of citrus flavanones including neohesperidin found antiosteoclastic and osteogenic effects in cell studies, with animal models showing reduced bone loss and increased bone mineral density. Clinical research in humans is still needed to confirm these effects translate to bone outcomes.
Neohesperidin itself has a distinctly bitter taste, unlike its sweet dihydrochalcone derivative. This bitterness is characteristic of bitter orange (Seville orange) peel and is part of why formulators need to account for flavour masking when using neohesperidin-standardised extract in oral products.
Related compounds: Hesperidin, Diosmin